APLS FY2025 EPS Estimate Increased by Cantor Fitzgerald

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Analysts at Cantor Fitzgerald upped their FY2025 earnings per share (EPS) estimates for Apellis Pharmaceuticals in a research note issued to investors on Wednesday, July 2nd. Cantor Fitzgerald analyst S. Seedhouse now expects that the company will post earnings of ($0.22) per share for the year, up from their previous forecast of ($2.38). Cantor Fitzgerald currently has a "Overweight" rating and a $44.00 target price on the stock. The consensus estimate for Apellis Pharmaceuticals' current full-year earnings is ($1.70) per share. Cantor Fitzgerald also issued estimates for Apellis Pharmaceuticals' FY2026 earnings at ($0.91) EPS.

Several other research firms have also recently weighed in on APLS. Raymond James Financial cut Apellis Pharmaceuticals from a "strong-buy" rating to an "outperform" rating and cut their price objective for the stock from $75.00 to $52.00 in a research report on Friday, May 9th. Morgan Stanley boosted their price objective on Apellis Pharmaceuticals from $25.00 to $26.00 and gave the stock an "equal weight" rating in a research report on Wednesday, July 2nd. Mizuho cut their price objective on Apellis Pharmaceuticals from $30.00 to $20.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 14th. Citigroup cut their price objective on Apellis Pharmaceuticals from $49.00 to $41.00 and set a "buy" rating on the stock in a research report on Thursday, May 22nd. Finally, Bank of America lowered Apellis Pharmaceuticals from a "buy" rating to a "neutral" rating and lowered their target price for the company from $41.00 to $23.00 in a research note on Friday, May 9th. Nine investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Apellis Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus price target of $39.79.

Apellis Pharmaceuticals Stock Performance

APLS stock traded down $0.84 during midday trading on Friday, hitting $17.42. The company's stock had a trading volume of 1,583,654 shares, compared to its average volume of 2,348,587. The stock's 50-day moving average price is $18.14 and its 200 day moving average price is $23.34. The company has a quick ratio of 3.62, a current ratio of 4.08 and a debt-to-equity ratio of 2.76. Apellis Pharmaceuticals has a 1 year low of $16.10 and a 1 year high of $42.47. The stock has a market cap of $2.19 billion, a price-to-earnings ratio of -9.73 and a beta of 0.67.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.38). Apellis Pharmaceuticals had a negative return on equity of 99.19% and a negative net margin of 28.83%. The business had revenue of $149.90 million during the quarter, compared to analysts' expectations of $197.61 million. During the same period in the prior year, the firm posted ($0.54) EPS. The firm's revenue for the quarter was down 3.2% on a year-over-year basis.

Hedge Funds Weigh In On Apellis Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. increased its stake in Apellis Pharmaceuticals by 26.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 307,709 shares of the company's stock worth $6,730,000 after acquiring an additional 64,742 shares during the last quarter. Voya Investment Management LLC increased its stake in Apellis Pharmaceuticals by 1.8% in the 1st quarter. Voya Investment Management LLC now owns 125,401 shares of the company's stock worth $2,743,000 after acquiring an additional 2,250 shares during the last quarter. Acadian Asset Management LLC boosted its holdings in shares of Apellis Pharmaceuticals by 1,146.2% in the 1st quarter. Acadian Asset Management LLC now owns 23,976 shares of the company's stock worth $522,000 after purchasing an additional 22,052 shares in the last quarter. Focus Partners Wealth boosted its holdings in shares of Apellis Pharmaceuticals by 118.4% in the 1st quarter. Focus Partners Wealth now owns 21,883 shares of the company's stock worth $479,000 after purchasing an additional 11,862 shares in the last quarter. Finally, Bayforest Capital Ltd boosted its holdings in shares of Apellis Pharmaceuticals by 431.9% in the 1st quarter. Bayforest Capital Ltd now owns 52,338 shares of the company's stock worth $1,145,000 after purchasing an additional 42,499 shares in the last quarter. 96.29% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Apellis Pharmaceuticals news, General Counsel David O. Watson sold 5,000 shares of the company's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $18.77, for a total value of $93,850.00. Following the transaction, the general counsel directly owned 133,730 shares in the company, valued at $2,510,112.10. This represents a 3.60% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 6.80% of the stock is owned by corporate insiders.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).